Meeting
2023 ASCO Annual Meeting
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
Authors
Laetitia A Mauti
Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland
Laetitia A Mauti , Tobias Finazzi , Lisa Holer , Adrienne Bettini , David König , Martin Früh , Simon Haefliger , Alfredo Addeo , Michael Thomas Mark , Martin Buess , Patrizia Froesch , Wolf Dieter Janthur , Christine Waibel , Christoph J. Ackermann , Patrick Dorn , Bernhard Scheibe , Miklos Pless , Matthias Guckenberger , Spasenija Savic Prince , Sacha Rothschild
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04245514
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8547)
DOI
10.1200/JCO.2023.41.16_suppl.8547
Abstract #
8547
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).
First Author: Markus Hecht
Poster
2020 ASCO Virtual Scientific Program
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
First Author: Sacha Rothschild
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour